Guidance on new treatments for early Alzheimer's disease issued

New therapies for early Alzheimer's disease, monoclonal antibodies that remove amyloid-β plaques in the brain, are bringing hope to people whose lives have been affected by the disease. To help neurologists discuss these ...


Q&A: Experts discuss pros, cons of new Alzheimer's drug

Patient care teams are preparing to offer lecanemab, a new Alzheimer's disease treatment expected to soon receive approval from the U.S. Food and Drug Administration (FDA), to patients in the coming months.

page 1 from 3